Conor Killmurray

Research presented at the EBMT meeting suggests cell expansion may be a good biomarker of both response and outcomes.

Seven patients from the trial continued to be followed-up as of the data cut-off date.

Surveyed oncologists supported the use of CAR T-cell therapy at higher rates than previous years.

Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.

Axicabtagene ciloleucel and tisagenlecleucel have been used mostly to treat patients with diffuse large B-cell lymphoma in the outpatient setting.

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial.

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas.